Brachial plexus injury

Myomo Provides Update on Progress to Obtain Medicare Part B Reimbursement for MyoPro

Retrieved on: 
Wednesday, December 7, 2022
Health Insurance, Insurance, Technology, Robotics, Physical Therapy, Managed Care, Professional Services, Medical Devices, Neurology, Wearables, Mobile Technology, Other Technology, Science, Health, Mobile, Wireless, Research, Security (finance), CMS, Coronavirus, Arm, EMG, Veterans Health Administration, Centers for Medicare & Medicaid Services, Financial compensation, CVA, Risk, Patient, Brachial plexus injury, Sale, Neuromuscular disease, Healthcare Common Procedure Coding System, Medicare Part D, Classification, Research, NYSE, Disclosure, ALS, Commission, HCPCS, Medicare Advantage, Medicaid, Health equity, COVID-19, History, DME, Annual report, Ohio Bureau of Workers' Compensation, Medicare (United States), Marketing, Stroke, Insurance, Medicare, Bureau, Health insurance, Life insurance, Pharmaceutical industry, Risk management

As background, Myomo was issued Healthcare Common Procedure Coding System (HCPCS) codes L8701 and L8702 by CMS, which became effective January 1, 2019.

Key Points: 
  • As background, Myomo was issued Healthcare Common Procedure Coding System (HCPCS) codes L8701 and L8702 by CMS, which became effective January 1, 2019.
  • At that time, CMS classified the MyoPro as durable medical equipment, or DME, which is reimbursed on a 13-month capped rental basis.
  • While these discussions have been taking place, no fee schedule rate has been set by CMS for the MyoPro.
  • Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S. and Germany, and other representatives internationally.

Ruling by German Social Court Supports MyoPro Reimbursement by Nation’s Statutory Health Insurance System

Retrieved on: 
Monday, December 5, 2022
Professional Services, Medical Devices, Health, Health Technology, Insurance, General Health, Lifting, Security (finance), Coronavirus, Arm, EMG, CVA, Risk, Federal Social Court, Patient, Brachial plexus injury, Neuromuscular disease, Massachusetts Institute of Technology, Sale, Spinal cord, Elbow, Paralysis, DAK, NYSE, Hand, ALS, Commission, COVID-19, Annual report, Motion, Harvard Medical School, Marketing, Stroke, Insurance, Health insurance, Medical imaging, Pharmaceutical industry, Risk management

As a result of this ruling, the third-largest German health insurance company, DAK, has been ordered to cover the costs for the MyoPro for the plaintiff.

Key Points: 
  • As a result of this ruling, the third-largest German health insurance company, DAK, has been ordered to cover the costs for the MyoPro for the plaintiff.
  • "With this ruling, a court has confirmed that the MyoPro is a device that can aid patients who suffer from upper extremity impairment and should be covered by statutory health insurance.
  • We expect this ruling will make it easier for patients like the plaintiff to obtain a MyoPro, said John Frijters, Managing Director of Myomo Europe GmbH.
  • The patented MyoPro technology was developed by Myomo in collaboration with researchers at the Massachusetts Institute of Technology and Harvard Medical School.

Myomo to Report Third Quarter Financial Results on November 10, 2022

Retrieved on: 
Thursday, November 3, 2022
General Health, Health Technology, Health, Medical Devices, Company, International, Internet, Arm, NYSE, Webcast, Stroke, PIN, Neuromuscular disease, ALS, Brachial plexus injury, CVA, Patient, EMG, Pharmaceutical industry

Myomo, Inc. (NYSE American: MYO) (Myomo or the Company), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2022 on November 10, 2022, after the market close.

Key Points: 
  • Myomo, Inc. (NYSE American: MYO) (Myomo or the Company), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2022 on November 10, 2022, after the market close.
  • The Company will host a conference call the same day, Thursday, November 10, 2022 at 4:30 p.m.
  • ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer.
  • Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S and representatives internationally.

Myomo to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Wednesday, September 7, 2022
Health Technology, Health, Medical Devices, NYSE, Arm, Lists of diseases, CVA, EMG, Brachial plexus injury, Conference, Stroke, Neuromuscular disease, ALS, Patient, Pharmaceutical industry

Myomo, Inc. (NYSE American: MYO) (Myomo or the Company), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference.

Key Points: 
  • Myomo, Inc. (NYSE American: MYO) (Myomo or the Company), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference.
  • The Conference is being held September 12 14, both virtually and in New York City.
  • A webcast of the presentation will be available on-demand beginning September 12, 2022 at 7:00 a.m. Eastern time here .
  • Management will be available for virtual one-on-one meetings with the investment community during the conference.

Myomo Receives Order from the Louis Stokes Cleveland VA Medical Center to Support MyoPro Clinical Trial

Retrieved on: 
Tuesday, August 30, 2022
Other Health, Research, General Health, Medical Devices, Defense, Health Technology, Clinical Trials, Science, Neurology, Veterans, Health, Physical Therapy, Security (finance), COVID-19, Medical Center, NYSE, Upper limb, Stroke, Commission, Arm, Insurance, Lists of diseases, Coronavirus, Veterans Health Administration, Fugl-Meyer Assessment of sensorimotor function, CVA, Sale, Risk, EMG, Brain, Department, U.S. Securities and Exchange Commission, Brachial plexus injury, Company, Neuromuscular disease, Marketing, ALS, Annual report, Assistant professor, Private Securities Litigation Reform Act, Patient, Pharmaceutical industry, Risk management, Research

Myomo, Inc. (NYSE American: MYO) (Myomo or the Company), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced receipt of a $120,000 order for MyoPro units from Clevelands Louis Stokes Veterans Administration (VA) Medical Center.

Key Points: 
  • Myomo, Inc. (NYSE American: MYO) (Myomo or the Company), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced receipt of a $120,000 order for MyoPro units from Clevelands Louis Stokes Veterans Administration (VA) Medical Center.
  • The units will be used in an investigator-initiated, randomized clinical trial led by Svetlana Pundik, M.D., Assistant Professor, Department of Neurology, Case Western Reserve University School of Medicine and Director, Brain Plasticity and Neural Recovery Research Laboratory and Staff Neurologist, Louis Stokes Cleveland VA Medical Center.
  • This study by the Cleveland VA represents an important addition to the established body of evidence documenting the benefits of MyoPro, said Harry Kovelman, M.D., Chief Medical Officer of Myomo.
  • Randomized clinical trials represent the highest level of research as viewed by clinical professionals and third-party payers.

Myomo to Report Second Quarter Financial Results on August 3, 2022

Retrieved on: 
Wednesday, July 27, 2022
Medical Devices, Health, PIN, NYSE, Brachial plexus injury, Webcast, EMG, Internet, Arm, ALS, Company, Patient, Lists of diseases, Stroke, International, CVA, Neuromuscular disease, Pharmaceutical industry

Myomo, Inc. (NYSE American: MYO) (Myomo or the Company), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and six months ended June 30, 2022 on August 3, 2022, after the market close.

Key Points: 
  • Myomo, Inc. (NYSE American: MYO) (Myomo or the Company), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and six months ended June 30, 2022 on August 3, 2022, after the market close.
  • The Company will host a conference call the same day, Wednesday, August 3, 2022 at 4:30 p.m.
  • ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer.
  • Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S and representatives internationally.

Myomo Announces Second Quarter Preliminary Revenue and Record Pipeline Additions

Retrieved on: 
Thursday, July 7, 2022
Wearables, Mobile Technology, Mobile, Wireless, Technology, Neurology, Biometrics, Biotechnology, Physical Therapy, General Health, Robotics, Health, Insurance, Centers for Medicare & Medicaid Services, Patient, JV, CMS, Marketing, Center, COVID-19, Stroke, Sale, Company, Advertising, U.S. Securities and Exchange Commission, ALS, Annual report, Lists of diseases, CVA, Security (finance), EMG, Private Securities Litigation Reform Act, NYSE, Brachial plexus injury, Arm, Risk, Neuromuscular disease, Medicare, Coronavirus, Commission, Pharmaceutical industry, Video game, Health insurance, Risk management

Myomo, Inc. (NYSE American: MYO) (Myomo or the Company), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces preliminary second quarter revenue and provides an update on its pipeline entering the third quarter.

Key Points: 
  • Myomo, Inc. (NYSE American: MYO) (Myomo or the Company), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces preliminary second quarter revenue and provides an update on its pipeline entering the third quarter.
  • Revenue for the second quarter of 2022 is expected to be $3.4 million to $3.6 million, an increase of 10% to 16% compared with the second quarter of 2021.
  • All revenue in the second quarter of 2022 was product revenue, as the Company did not receive payment of the remaining license fee from its joint venture partner in China.
  • Also, Myomo expects to report more than 400 additions to its pipeline of prospective MyoPro patients, a quarterly record, which reflects continued success with its new marketing and advertising strategies.

Myomo To Present at the Sidoti Summer Small Cap Virtual Investor Conference

Retrieved on: 
Thursday, June 9, 2022
Biotechnology, Health, Medical Devices, Neuromuscular disease, Time, Stroke, Conference, CVA, Patient, ALS, NYSE, Lists of diseases, Arm, Brachial plexus injury, EMG, Pharmaceutical industry, Sidoti

Myomo is scheduled to present on June 15, 2022 at 4:00 p.m.

Key Points: 
  • Myomo is scheduled to present on June 15, 2022 at 4:00 p.m.
  • Myomo will also host virtual one-on-one meetings with investors on Wednesday and Thursday, June 15 and 16, 2022.
  • Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis.
  • Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally.

Myomo Reports First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 11, 2022
Biotechnology, General Health, Medical Devices, Other Health, Health, PIN, Company, International, EBITDA, Private Securities Litigation Reform Act, Neuromuscular disease, U.S. Securities and Exchange Commission, Annual report, Webcast, Environment, Patient, Brachial plexus injury, Insurance, Coronavirus, Review, Stroke, Operating cost, Commission, COVID-19, Marketing, EMG, Industry, Growth, Risk, Sale, Lists of diseases, Security (finance), GAAP, CVA, Arm, ALS, Table, Video game, Bank, Risk management

Product revenue for the first quarter of 2022 was $2.9 million, an increase of 23% compared with the first quarter of 2021.

Key Points: 
  • Product revenue for the first quarter of 2022 was $2.9 million, an increase of 23% compared with the first quarter of 2021.
  • Myomo recognized revenue on 71 units in the first quarter of 2022, an increase of 9% compared with the fourth quarter of 2021.
  • Operating expenses for the first quarter of 2022 were $5.3 million, an increase of 14% compared with the first quarter of 2021.
  • Operating loss for the first quarter of 2022 decreased to $2.7 million from $2.9 million for the first quarter of 2021.

Myomo to Report First Quarter Financial Results on May 11, 2022

Retrieved on: 
Wednesday, May 4, 2022
Biotechnology, General Health, Medical Devices, Other Health, Health, Arm, Lists of diseases, Company, NYSE, Stroke, Patient, Webcast, Internet, International, Neuromuscular disease, PIN, CVA, EMG, ALS, Brachial plexus injury, Pharmaceutical industry

Myomo, Inc. (NYSE American: MYO) (Myomo or the Company), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months ended March 31, 2022 on May 11, 2022 after the market close.

Key Points: 
  • Myomo, Inc. (NYSE American: MYO) (Myomo or the Company), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months ended March 31, 2022 on May 11, 2022 after the market close.
  • The Company will host a conference call the same day, Wednesday, May 11, 2022 at 4:30 p.m.
  • ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer.
  • Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S and representatives internationally.